Last reviewed · How we verify
AMG820 and pembrolizumab
AMG820 is a monoclonal antibody targeting CD28 and pembrolizumab is a monoclonal antibody targeting PD-1.
AMG820 is a monoclonal antibody targeting CD28 and pembrolizumab is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, Melanoma.
At a glance
| Generic name | AMG820 and pembrolizumab |
|---|---|
| Sponsor | AmMax Bio, Inc. |
| Drug class | PD-1 inhibitor and CD28 antagonist |
| Target | PD-1 and CD28 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
AMG820 and pembrolizumab work by binding to their respective targets, thereby modulating the immune response.
Approved indications
- Non-small cell lung cancer
- Melanoma
Common side effects
- Pneumonitis
- Diarrhea
- Fatigue
Key clinical trials
- Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG820 and pembrolizumab CI brief — competitive landscape report
- AMG820 and pembrolizumab updates RSS · CI watch RSS
- AmMax Bio, Inc. portfolio CI